Neuroinflammation and neuroprogression in depression: Effects of alternative drug treatments

Neuroinflammation and neuroprogression in depression: Effects of alternative drug treatments

Given that available antidepressant pharmacotherapies are not optimally effective, there is a need for alternative treatment options that are rooted in a comprehensive understanding of the illness's pathophysiology. Major depressive disorder (MDD) has been historically attributed to monoamine,...

Full description

Bibliographic Details
Main Authors:	Brandon Richardson, Andrew MacPherson, Francis Bambico
Format:	Article
Language:	English
Published:	Elsevier 2022-12-01
Series:	Brain, Behavior, & Immunity - Health
Subjects:	Inflammation Cytokine Depression Major depressive disorder (MDD) Neuroplasticity Neuroprogression
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666354622001442

Similar Items

Neuroprogression: the hidden mechanism of depression
by: Labra Ruiz NA, et al.
Published: (2018-10-01)

Antidepressant mechanisms of ketamine: a review of actions with relevance to treatment-resistance and neuroprogression
by: August P. M. Lullau, et al.
Published: (2023-08-01)

Heterogeneous trajectories in schizophrenia: insights from neurodevelopment and neuroprogression models
by: Ramiro Reckziegel, et al.

Biological Pathways Associated with Neuroprogression in Bipolar Disorder
by: Bianca Wollenhaupt-Aguiar, et al.
Published: (2021-02-01)

Nutritional ketosis as an intervention to relieve astrogliosis: Possible therapeutic applications in the treatment of neurodegenerative and neuroprogressive disorders
by: Gerwyn Morris, et al.
Published: (2020-01-01)

Underdiagnosis of Major Depressive Episodes in Hemodialysis Patients: The Need for Screening and Patient Education
by: Wojciech Orzechowski, et al.
Published: (2021-09-01)

Staging and neuroprogression in bipolar disorder: a systematic review of the literature
by: Clarissa Severino Gama, et al.
Published: (2013-03-01)

The effect of exercise interventions on inflammatory markers in major depressive disorder: protocol for a systematic review and meta-analysis [version 3; peer review: 2 approved]
by: Diana Grunberg, et al.
Published: (2022-06-01)

Neuroprogression as an Illness Trajectory in Bipolar Disorder: A Selective Review of the Current Literature
by: Gianluca Serafini, et al.
Published: (2021-02-01)

Efficacy and safety of zuranolone in the treatment of major depressive disorder: a meta-analysis
by: Shuyu Wang, et al.
Published: (2024-01-01)

Melanopsin-Driven Pupil Response and Light Exposure in Non-seasonal Major Depressive Disorder
by: Beatrix Feigl, et al.
Published: (2018-09-01)

Bipolar Disorder and Immune Dysfunction: Epidemiological Findings, Proposed Pathophysiology and Clinical Implications
by: Joshua D. Rosenblat, et al.
Published: (2017-10-01)

Treatment-Resistant Depression in Poland—Epidemiology and Treatment
by: Piotr Gałecki, et al.
Published: (2022-01-01)

The Impact of Residual Symptoms in Major Depression
by: Joshua A. Israel
Published: (2010-08-01)

Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Plus a Newly Initiated Oral Antidepressant in Adult Patients with Treatment-Resistant Depression: A Randomized, Double-Blind, Multicenter, Active-Controlled Study Conducted in China and USA
by: Chen X, et al.
Published: (2023-03-01)

Sex differences in gut microbiota in patients with major depressive disorder
by: Chen JJ, et al.
Published: (2018-02-01)

Depression-related stigma among primary care providers
by: Andrew Kluemper, PharmD, BCPS, BCPP, et al.
Published: (2021-05-01)

EFFECT OF SINGLE DOSE OF KETAMINE IN PATIENTS OF MAJOR DEPRESSIVE DISORDER-A PAKISTANI PERSPECTIVE
by: Muhammad Siddique Kakar, et al.
Published: (2020-10-01)

EFFECT OF SINGLE DOSE OF KETAMINE IN PATIENTS OF MAJOR DEPRESSIVE DISORDER-A PAKISTANI PERSPECTIVE
by: Muhammad Siddique Kakar, et al.
Published: (2020-10-01)

Effect of medical education on European psychiatrists’ knowledge in management of major depressive disorder and psychiatric emergencies
by: L. Thevathasan, et al.
Published: (2022-06-01)

Effect of medical education on European primary care physicians’ knowledge in management of major depressive disorder and psychiatric emergencies
by: L. Thevathasan, et al.
Published: (2022-06-01)

SUMOylation and Major Depressive Disorder
by: Seok-Won Jeoung, et al.
Published: (2022-07-01)

The molecular pathophysiology of depression and the new therapeutics
by: Haihua Tian, et al.
Published: (2022-09-01)

A link between ghrelin and major depressive disorder: a mini review
by: Michał Lis, et al.
Published: (2024-03-01)

Understanding the Role of Oxidative Stress, Neuroinflammation and Abnormal Myelination in Excessive Aggression Associated with Depression: Recent Input from Mechanistic Studies
by: Anna Gorlova, et al.
Published: (2023-01-01)

Efficacy and tolerability of minocycline in depressive patients with or without treatment-resistant: a meta-analysis of randomized controlled trials
by: Youjia Qiu, et al.
Published: (2023-06-01)

Investigating the effect of magnesium supplement in patients with major depressive disorder under selective serotonin reuptake inhibitor treatment
by: Masoumeh Nazarinasab, et al.
Published: (2022-01-01)

Disrupted Spatiotemporal Complexity of Resting-State Electroencephalogram Dynamics Is Associated With Adaptive and Maladaptive Rumination in Major Depressive Disorder
by: Jing Wang, et al.
Published: (2022-05-01)

Reliability and Validity of THINC-it in Evaluating Cognitive Function of Patients with Bipolar Depression
by: Zhang W, et al.
Published: (2020-10-01)

The Association of HHV-6 and the <i>TNF-α</i> (-308G/A) Promotor with Major Depressive Disorder Patients and Healthy Controls in Thailand
by: Sasiwimon Sumala, et al.
Published: (2023-09-01)

Development and validation of a nomogram based on lymphocyte subsets to distinguish bipolar depression from major depressive disorder
by: Liming Su, et al.
Published: (2022-10-01)

Evaluation of serum amino acids and non-enzymatic antioxidants in drug-naïve first-episode major depressive disorder
by: Md. Rabiul Islam, et al.
Published: (2020-06-01)

Metabolic and Microbiota Measures as Peripheral Biomarkers in Major Depressive Disorder
by: Rachael Horne, et al.
Published: (2018-10-01)

Gender differences in prevalence and clinical correlates of anxiety symptoms in first-episode and drug-naïve patients with major depressive disorder
by: Wan-Qiu Yang, et al.
Published: (2021-11-01)

Clinical and Biological Factors Are Associated with Treatment-Resistant Depression
by: Massimiliano Buoli, et al.
Published: (2022-02-01)

Association of Psilocybin Use in Adolescents with Major Depressive Episode
by: K. Shah, et al.
Published: (2022-06-01)

Suicide risk in patients with a current depressive episode during the COVID-19 pandemic
by: Mikhail Zinchuk, et al.
Published: (2024-04-01)

The core inflammatory factors in patients with major depressive disorder: a network analysis
by: Yexian Zeng, et al.
Published: (2023-08-01)

Retracing our steps to understand ketamine in depression: A focused review of hypothesized mechanisms of action
by: Madison N. Irwin, PharmD, et al.
Published: (2021-05-01)

Biological correlates of treatment resistant depression: a review of peripheral biomarkers
by: Emiliana Mancuso, et al.
Published: (2023-10-01)